These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7566482)

  • 1. Response of the damaged dopamine system to GM1 and semisynthetic gangliosides: effects of dose and extent of lesion.
    Schneider JS; Distefano L
    Neuropharmacology; 1995 May; 34(5):489-93. PubMed ID: 7566482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. LIGA 20 increases striatal dopamine levels in aged MPTP-treated mice refractory to GM1 ganglioside treatment.
    Schneider JS; DiStefano L
    Neuroreport; 1993 Nov; 5(2):103-4. PubMed ID: 8110995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral administration of semisynthetic sphingolipids promotes recovery of striatal dopamine concentrations in a murine model of parkinsonism.
    Schneider JS; DiStefano L
    Neurology; 1994 Apr; 44(4):748-50. PubMed ID: 8164837
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of age on GM1 ganglioside-induced recovery of concentrations of dopamine in the striatum in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mice.
    Schneider JS
    Neuropharmacology; 1992 Feb; 31(2):185-92. PubMed ID: 1553028
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment with GM1 ganglioside restores striatal dopamine in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated mouse.
    Hadjiconstantinou M; Neff NH
    J Neurochem; 1988 Oct; 51(4):1190-6. PubMed ID: 3262149
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GM1 gangliosides alter acute MPTP-induced behavioral and neurochemical toxicity in mice.
    Fazzini E; Durso R; Davoudi H; Szabo GK; Albert ML
    J Neurol Sci; 1990 Oct; 99(1):59-68. PubMed ID: 2250172
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Exogenous GM1 gangliosides induce partial recovery of the nigrostriatal dopaminergic system in MPTP-treated young mice but not in aging mice.
    Date I; Felten SY; Felten DL
    Neurosci Lett; 1989 Dec; 106(3):282-6. PubMed ID: 2601883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. GM1 ganglioside treatment promotes recovery of striatal dopamine concentrations in the mouse model of MPTP-induced parkinsonism.
    Schneider JS; Yuwiler A
    Exp Neurol; 1989 Aug; 105(2):177-83. PubMed ID: 2568945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of L-deprenyl treatment, alone and combined with GM1 ganglioside, on striatal dopamine content and substantia nigra pars compacta neurons.
    Rothblat DS; Schneider JS
    Brain Res; 1998 Jan; 779(1-2):226-30. PubMed ID: 9473679
    [TBL] [Abstract][Full Text] [Related]  

  • 10. GM1 ganglioside rescues substantia nigra pars compacta neurons and increases dopamine synthesis in residual nigrostriatal dopaminergic neurons in MPTP-treated mice.
    Schneider JS; Kean A; DiStefano L
    J Neurosci Res; 1995 Sep; 42(1):117-23. PubMed ID: 8531220
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recovery from experimental parkinsonism in primates with GM1 ganglioside treatment.
    Schneider JS; Pope A; Simpson K; Taggart J; Smith MG; DiStefano L
    Science; 1992 May; 256(5058):843-6. PubMed ID: 1350379
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GM1 ganglioside-induced recovery of nigrostriatal dopaminergic neurons after MPTP: an immunohistochemical study.
    Hadjiconstantinou M; Mariani AP; Neff NH
    Brain Res; 1989 Apr; 484(1-2):297-303. PubMed ID: 2565752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Administration of GM1 ganglioside restores the dopamine content in striatum after chronic treatment with MPTP.
    Hadjiconstantinou M; Rossetti ZL; Paxton RC; Neff NH
    Neuropharmacology; 1986 Sep; 25(9):1075-7. PubMed ID: 3490632
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of GM1 ganglioside treatment on dopamine innervation of the striatum of MPTP-treated mice.
    Rothblat DS; Schneider JS
    Ann N Y Acad Sci; 1998 Jun; 845():274-7. PubMed ID: 9668361
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of GM1 ganglioside treatment on pre- and postsynaptic dopaminergic markers in the striatum of parkinsonian monkeys.
    Pope-Coleman A; Tinker JP; Schneider JS
    Synapse; 2000 May; 36(2):120-8. PubMed ID: 10767059
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhanced susceptibility to kainate-induced seizures, neuronal apoptosis, and death in mice lacking gangliotetraose gangliosides: protection with LIGA 20, a membrane-permeant analog of GM1.
    Wu G; Lu ZH; Wang J; Wang Y; Xie X; Meyenhofer MF; Ledeen RW
    J Neurosci; 2005 Nov; 25(47):11014-22. PubMed ID: 16306414
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced restoration of striatal dopamine concentrations by combined GM1 ganglioside and neurotrophic factor treatments.
    Schneider JS; DiStefano L
    Brain Res; 1995 Mar; 674(2):260-4. PubMed ID: 7796105
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Administration of GM1 ganglioside eliminates neuroleptic-induced sensorimotor deficits in MPTP-treated mice.
    Weihmuller FB; Hadjiconstantinou M; Bruno JP; Neff NH
    Neurosci Lett; 1988 Oct; 92(2):207-12. PubMed ID: 2903475
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential recovery of sensorimotor function in GM1 ganglioside-treated vs. spontaneously recovered MPTP-treated cats: partial striatal dopaminergic reinnervation vs. neurochemical compensation.
    Schneider JS; Schroeder JA; Rothblat DS
    Brain Res; 1998 Nov; 813(1):82-7. PubMed ID: 9824674
    [TBL] [Abstract][Full Text] [Related]  

  • 20. GM1 ganglioside treatment partially reverses the nigrostriatal dopamine defect in the weaver mutant mouse.
    Schneider JS; Smith MG; DiStefano L; Berrian J
    Brain Res; 1994 Feb; 636(2):353-6. PubMed ID: 7912161
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.